Publications

Read Now

February 2019 (Revised August 2019)
Case

Maccabitech: The Promise of Israel's Healthcare Data

By: Scott Duke Kominers and Carin-Isabel Knoop

Dr. Varda Shalev bridges technology and medicine through Maccabitech, a "research and innovation wing" of Israel's Maccabi Healthcare Services (MHS) that partners with research institutions, pharmaceutical companies, and startups. Shalev hopes to scale Maccabitech's... View Details

Keywords: Big Data; Healthcare; Analytics and Data Science; Digital Platforms; Health Care and Treatment; Innovation and Invention; Research; Entrepreneurship; Risk Management; Israel

February 2011 (Revised June 2011)
Case

Hardina Smythe and the Healthcare Investment Conundrum

By: Matthew Rhodes-Kropf, Ann Leamon and Lisa Strope

Hardina Smythe, a recent MBA graduate, has just joined a top-tier venture capital firm in the difficult environment of late 2010. Her first assignment is to evaluate three different deals and make recommendations to the partners. Each potential investment has strengths... View Details

Keywords: Venture Capital; Asset Management; Private Equity; Entrepreneurship; Investment; Health Care and Treatment; Innovation and Invention; Financial Services Industry

30 Sep 2002
Research & Ideas

Use the Psychology of Pricing To Keep Customers Returning

same concept can be applied to health care. In its current form, most of us pay for blanket health care coverage that entitles us to a number of periodic services such as... View Details

Keywords: by Manda Mahoney

10 May 2016
First Look

May 10, 2016

Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=51040 forthcoming American Journal of Health Promotion The Effect of Cost Sharing on an Employee Weight Loss Program: A Randomized Trial By: John, Leslie K., Andrea Troxel,... View Details

Keywords: Carmen Nobel

21 May 2013
First Look

First Look: May 21

acceptance and a widespread consensus among both internal and external stakeholders. The outcome of this type of professional competition is not determined by claims about representing the underlying economic reality, but by claims about representing those who View Details

Keywords: Sean Silverthorne

02 Sep 2002
What Do You Think?

What Can Business Schools Do to Avoid Bad Apples?

Summing Up This month's column resulted in a number of suggestions for sorting out the "bad apples" among applicants to MBA programs across the country. But just as many respondents questioned the underlying assumptions of the column. Many respondents... View Details

Keywords: by James Heskett

12 Jan 2016
First Look

January 12, 2016

link: https://www.hbs.edu/faculty/Pages/item.aspx?num=50304 October 2015 Health Affairs Exposure to Harmful Workplace Practices Could Account for Inequality in Life Spans Across Different Demographic Groups By: Goh, Joel, Jeffrey Pfeffer,... View Details

Keywords: Carmen Nobel

18 Nov 2010
Research & Ideas

GM’s IPO: Back to the Future

alter significantly how people think about the company, its products, and the brand. US consumers have not had a high-quality perception of GM brands over the past few decades. Although driven in part by the company's missteps, the View Details

Keywords: by Staff; Auto

2014
Working Paper

Bio-Piracy or Prospering Together? Fuzzy Set and Qualitative Analysis of Herbal Patenting by Firms

By: Prithwiraj Choudhury and Tarun Khanna

Since the 1990s, several Western firms have filed patents based on medicinal herbs from emerging markets, evoking protests from local stakeholders against 'bio-piracy'. We explore conditions under which firms and local stakeholders share rents from such patents. Our... View Details

Keywords: Rents From New Technology; Local Stakeholders; Herbal Patents; QCA; Fuzzy Set Analysis; Qualitative Case Studies; Plant-Based Agribusiness; Patents; Emerging Markets; Health Care and Treatment; Business and Stakeholder Relations; Cross-Cultural and Cross-Border Issues; Agriculture and Agribusiness Industry; Pharmaceutical Industry

Read Now

August 2009 (Revised April 2012)
Case

Genzyme's CSR Dilemma: How to Play its HAND

By: Christopher A. Bartlett, Tarun Khanna and Prithwiraj Choudhury

Genzyme, a global biotechnology company, launches a program to develop therapies for neglected diseases (e.g., malaria, TB), giving away the intellectual property. This case focuses on the decision of which diseases, which partnerships, and which markets should... View Details

Keywords: Global Strategy; Health Care and Treatment; Intellectual Property; Corporate Social Responsibility and Impact; Partners and Partnerships; Research and Development; Biotechnology Industry

29 Apr 2020
Book

The Key to Powerful Social Change: Small Villages

Who will solve the great problems facing humanity, a list of critical issues that only begins with the current pandemic? In the interview below, Rosabeth Moss Kanter discusses her recent book, Think Outside the Building, and her view that solutions are most likely to... View Details

Keywords: by Dina Gerdeman

August 2008 (Revised May 2009)
Background Note

Note on Generic Drugs in the European Union

By: Robert C. Pozen and Elizabeth M. Leonard

Rules governing the introduction of generic drugs in U.S. and EU have some similarities but significant differences because of the Hatch-Waxman Act in the U.S. View Details

Keywords: Governing Rules, Regulations, and Reforms; Government Legislation; Health Care and Treatment; Trademarks; Brands and Branding; Pharmaceutical Industry; European Union; United States

Find at Harvard

August 2001
Case

Scios, Inc.

By: Regina E. Herzlinger

Scios, filled with distinguished scientists and experienced managers, nevertheless fails to clear the FDA Phase III process for an important biotechnology drug. This case asks the students to analyze the social costs and benefits of the regulatory process. View Details

Keywords: Governing Rules, Regulations, and Reforms; Health Care and Treatment; Cost Management; Cost vs Benefits; Social Issues; Pharmaceutical Industry; United States

October 2021 (Revised January 2022)
Supplement

Michael Ku and Global Clinical Supply at Pfizer Inc.: Bringing Hope to Patients (C)

By: Linda A. Hill and Emily Tedards

This case is the third installment in a series about the 10-year cultural and digital transformation of Pfizer’s Global Clinical Supply organization. In 2011, Michael Ku became Pfizer’s Vice President of Global Clinical Supply (GCS) after the company had undergone... View Details

Keywords: Clinical Supply Chain; COVID-19; Vaccine; Agile; Innovation and Invention; Change Management; Organizational Culture; Transformation; Leadership; Corporate Strategy; Health Pandemics; Crisis Management; Mission and Purpose; Health Care and Treatment; Supply Chain Management; Digital Transformation